首页> 外文期刊>Techniques in regional anesthesia & pain management. >Current understanding of safety and efficacy of stem cell therapy for discogenic pain-A systematic review of human studies
【24h】

Current understanding of safety and efficacy of stem cell therapy for discogenic pain-A systematic review of human studies

机译:目前了解干细胞治疗对脑膜疼痛的安全性和有效性 - 对人类研究的系统综述

获取原文
获取原文并翻译 | 示例

摘要

This study is a systematic review of human clinical studies of stem cell therapy for discogenic pain. To summarize the current human trials and feasibility studies involving mesenchymal stem cell (MSC) therapy for treatment of discogenic pain. A search of Ovid databases and Clinicaltrials.gov was conducted from inception through July 2016. We included human clinical trials and case reports that evaluated treatment with injected MSCs for patients with discogenic back pain. The outcomes of interest for published studies included pain score, Oswestry Disability Index, and T2-weighted magnetic resonance imaging signal intensity indicative of water content of the nucleus pulposus. The initial search in Ovid databases using the selected search terms identified 408 results, of which 11 were included in this review based on selection criteria. This includes 6 completed studies and 5 ongoing clinical trials, 4 of which were confirmed active at the time of retrieval. In the 6 completed studies involving intradiscal stem cell injections, improvement in pain score, Oswestry Disability Index, and T2-weighted magnetic resonance imaging signal intensity of nucleus pulposus were reported. Currently active clinical trials focus on establishing safety, tolerability, and efficacy with respect to injected MSCs for discogenic pain. Although pain and functional benefit have been reported in association with stem cell therapy, longer-term safety studies and more randomized controlled trials are needed to examine the safety and efficacy of stem cell therapy for discogenic pain.
机译:本研究是对致畸疼痛的干细胞疗法人类临床研究的系统审查。总结当前的人类试验和可行性研究,涉及间充质干细胞(MSC)治疗治疗致畸疼痛。搜索OVID数据库和ClinicalTrials.gov于2016年7月从初始进行。我们包括人类临床试验和病例报告,评估了对椎间露背痛的患者注射MSC的治疗。发表研究的兴趣结果包括疼痛评分,OsWestry残疾指数和T2加权磁共振成像信号强度,其含有核浆气的含水量。使用所选搜索术语在OVID数据库中的初始搜索确定了408个结果,其中11个基于选择标准在本综述中包含。这包括6种完成的研究和5项正在进行的临床试验,其中4个在检索时被证实活跃。在6种完成的研究中,涉及体内干细胞注射的研究,报道了疼痛评分的改善,Oswestry残疾指数和核浆气的T2加权磁共振成像信号强度。目前活跃的临床试验专注于建立安全性,耐受性和疗效,以致脑疼痛。虽然已经与干细胞疗法有关的疼痛和功能性益处,但需要长期安全性研究和更多随机对照试验来检查干细胞治疗对致畸疼痛的安全性和功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号